LY 3056480

Drug Profile

LY 3056480

Alternative Names: LY-3056480

Latest Information Update: 26 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Audion Therapeutics
  • Class
  • Mechanism of Action Amyloid precursor protein secretase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Sensorineural hearing loss

Most Recent Events

  • 22 May 2017 Audion therapeutics plans a phase I/II trial for Sensorineural hearing loss (In adults, In the elderly) in Germany, Greece and United Kingdom (Intratympanic) (ISRCTN59733689)
  • 01 Jul 2016 Phase-I/II clinical trials in Sensorineural hearing loss (In adults, In the elderly) in Greece, Germany, United Kingdom (Intratympanic) (ISRCTN59733689)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top